Many new drugs and hold the cancer in chess, can defeat him. You add to the disease but additional weak spots, where you could bring a second attacker to complete case reports, the Vienna researchers.
The scientists Christoph Bock research center for Molecular medicine (CeMM) of the Austrian Academy of Sciences (ÖAW) sought and found in chronic blood cancer targets for such a double blow. The study appeared in the journal “Nature Chemical Biology”.
such vulnerabilities to identify, among the Team, what changes in gene regulation (epigenetic changes) since 2014-approved drug Ibrutinib in the cancer cells of patients with “chronic lymphocytic leukemia” (CLL) was looking for.
Severe adverse reactions
The active ingredient stops the uncontrolled growth of the immune cells and allows for even high-risk patients have a long Survival. You have to take it daily and severe side effects such as fever, pain, and constant fatigue are suffering.
The researchers tested the blood samples of patients who were treated with Ibrutinib, whether there are drugs that kill specifically the weakened leukemia cells. Such there were, and these were inhibitors for different signal transducer of cancer cells that allow them to unbridled growth.
With such drug combinations, one could make the leukemia in the future, maybe so hard that the treatment can be discontinued after some time, without any negative effects, the researchers said in a statement.
(oli/sda)
Created: 28.01.2019, 17:27 PM
